scholarly journals Short-term treatment effects produced by the Twin-block appliance: a systematic review and meta-analysis

2014 ◽  
Vol 37 (2) ◽  
pp. 170-176 ◽  
Author(s):  
Sayeh Ehsani ◽  
Brian Nebbe ◽  
David Normando ◽  
Manuel O. Lagravere ◽  
Carlos Flores-Mir
Keyword(s):  
Systematic Review ◽  
Treatment Effects ◽  
Meta Analysis ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment ◽  
Twin Block

Antidepressants in short-term treatment of binge eating disorder: Systematic review and meta-analysis

2008 ◽  
Vol 9 (2) ◽  
pp. 129-136 ◽  
Author(s):  
Sérgio Carlos Stefano ◽  
Josué Bacaltchuk ◽  
Sérgio Luís Blay ◽  
José Carlos Appolinário
Keyword(s):  
Systematic Review ◽  
Eating Disorder ◽  
Binge Eating ◽  
Binge Eating Disorder ◽  
Meta Analysis ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment

scholarly journals Aloe vera Is Effective and Safe in Short-term Treatment of Irritable Bowel Syndrome: A Systematic Review and Meta-analysis

2018 ◽  
Vol 24 (4) ◽  
pp. 528-535 ◽  
Author(s):  
Seung Wook Hong ◽  
Jaeyoung Chun ◽  
Sunmin Park ◽  
Hyun Jung Lee ◽  
Jong Pil Im ◽  
...  
Keyword(s):  
Systematic Review ◽  
Irritable Bowel Syndrome ◽  
Meta Analysis ◽  
Aloe Vera ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment ◽  
Irritable Bowel

Short-Term Treatment Effects of a Substance Use Disorder Therapy Involving Traditional Amazonian Medicine

2019 ◽  
Vol 51 (4) ◽  
pp. 323-334 ◽  
Author(s):  
Ilana Berlowitz ◽  
Heinrich Walt ◽  
Christian Ghasarian ◽  
Fernando Mendive ◽  
Chantal Martin-Soelch
Keyword(s):  
Substance Use ◽  
Substance Use Disorder ◽  
Treatment Effects ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment

The short-term treatment effects on the microbiota at the dorsum of the tongue in intra-oral halitosis patients—a randomized clinical trial

2012 ◽  
Vol 17 (2) ◽  
pp. 463-473 ◽  
Author(s):  
Seida Erovic Ademovski ◽  
G. Rutger Persson ◽  
Edwin Winkel ◽  
Albert Tangerman ◽  
Peter Lingström ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Treatment Effects ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment

scholarly journals DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines

2020 ◽  
Vol 4 (7) ◽  
pp. 1512-1517 ◽  
Author(s):  
Ignacio Neumann ◽  
Ariel Izcovich ◽  
Yuqing Zhang ◽  
Gabriel Rada ◽  
Susan R. Kahn ◽  
...  
Keyword(s):  
Systematic Review ◽  
Major Bleeding ◽  
Meta Analysis ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Treatment Phase ◽  
Term Treatment ◽  
Cochrane Central Register ◽  
Medical Patients ◽  
Short Term Treatment

Abstract Venous thromboembolism (VTE) is a relatively frequent complication in hospitalized patients, especially in those with risk factors. The benefit of using direct oral anticoagulants (DOACs) for prevention is controversial. This systematic review was performed as part of the American Society of Hematology (ASH) guidelines on VTE, developed in partnership with McMaster University. MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Epistemonikos were used as data sources from date of inception to November 2019. We included randomized trials in patients hospitalized for an acute medical disease, evaluating any DOACs vs other pharmacological prophylaxis, and included 3 trials with low risk of bias. We analyzed the effects of DOACs vs low-molecular-weight heparins (LMWHs) at 2 different time points: at the end of the short-term treatment phase (both drugs given for the same period of time) and at the end of the extended prophylaxis period (extended DOACs vs a shorter course of LMWHs). We observed that the use of DOACs did not reduce the risk of pulmonary embolism or symptomatic deep venous thrombosis (DVT) in comparison with LMWHs. However, the risk of major bleeding was slightly increased. Additionally, we observed that the benefit of DOACs previously reported was largely based on the reduction of asymptomatic DVT and was not apparent when only symptomatic events were considered. The use of DOACs in hospitalized medical patients slightly increases the risk of major bleeding with no appreciable benefit over LMWHs.

Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis

2010 ◽  
Vol 17 (5) ◽  
pp. 541-549 ◽  
Author(s):  
Maria Pia Sormani ◽  
Bettina Stubinski ◽  
Peter Cornelisse ◽  
Sanda Rocak ◽  
David Li ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Magnetic Resonance ◽  
Treatment Effects ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment ◽  
Pooled Data ◽  
Secondary Progressive ◽  
Relapsing Remitting ◽  
T2 Mri

Background: Use of quantitative magnetic resonance imaging (MRI) metrics as surrogates for clinical outcomes in multiple sclerosis (MS) trials is controversial. Objectives: We sought to validate, at the individual-patient level, the number of MRI active lesions, as a surrogate marker for relapses in MS. Methods: Individual-patient data from two large, placebo-controlled clinical trials of subcutaneous interferon β-1a in patients with relapsing–remitting or secondary progressive (SP) MS were analysed separately and as pooled data. The four Prentice criteria were applied to assess surrogacy for the number of new T2 MRI lesions. The predictive value of short-term treatment effects on this MRI marker for longer-term clinical relapses was also assessed. Results: All Prentice criteria were satisfied. The number of new T2 MRI lesions correlated with the number of relapses over the follow-up period. The proportion of treatment effect on relapses accounted for by the effect of treatment on new T2 MRI lesions over 2 years was 53% in patients with relapsing–remitting MS, 67% in patients with secondary progressive MS, and 62% in pooled data. In the pooled data, treatment effects on new lesions over 1 year mediated a good proportion (70%) of effects on relapses over the subsequent year. Conclusions: This study provides evidence that new T2 MRI lesion count is a surrogate for relapses in patients with MS treated with interferon or drugs with a similar mechanism of action. Short-term treatment effects on this MRI measure can predict longer-term effects on relapses.

Sign in / Sign up

Export Citation Format

Share Document